---

---

results   tags : Liver   

save search

---

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
ONVO | $1.25 11.61% 300K |

Health Technology

| 10.88% | O: 64.34% H: 4.82% C: -18.67%
fxr314 metabolic liver positive for results

---

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Published: 2024-02-26 (Crawled : 07:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21% |

Health Technology

| Email alert Add to watchlist
pharma liver disease fibrosis trial results

---

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023
Published: 2023-11-13 (Crawled : 20:00) - prnewswire.com
LPCN | $5.44 2.26% 8.9K |

Health Technology

| 91.37% | O: -2.52% H: 6.27% C: -0.92%
meeting liver presentation results phase 2

---

CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting®
Published: 2023-11-13 (Crawled : 14:30) - biospace.com/
CBAY | $32.48 0.03% 8.4M |

Health Technology

| 118.51% | O: 7.07% H: 6.73% C: 6.03%
meeting liver presentation results

---

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023
Published: 2023-11-10 (Crawled : 13:30) - globenewswire.com
SGMT | $4.07 72K |

Health Technology

| 45.36% | O: 5.0% H: 0.0% C: -12.07%
meeting liver preclinical potential results

---

Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
Published: 2023-11-10 (Crawled : 13:00) - globenewswire.com
ALGS | $0.785 -0.25% 150K |

Health Technology

| 8.44% | O: 0.0% H: 1.3% C: -9.26%
alg-0001 meeting hepatitis liver alg-000184 positive treatment therapeutics results

---

Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins
Published: 2023-10-10 (Crawled : 11:00) - globenewswire.com
AKRO | $21.29 -1.44% 160K |

Health Technology

| -55.11% | O: -59.06% H: 0.0% C: -8.66%
liver fibrosis therapeutics results insulin nash

---

Better Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep Advances
Published: 2023-10-05 (Crawled : 12:00) - biospace.com/
BTTX | $0.009 180K |

| -97.3% | O: 1.13% H: 5.96% C: -7.68%
liver disease publication therapeutics results study

---

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
Published: 2023-06-30 (Crawled : 05:00) - globenewswire.com
GNFT | $3.63 2.4K |

Health Technology

| -10.37% | O: 0.0% H: 0.99% C: -12.59%
elative rare liver disease positive trial results

---

Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
Published: 2023-05-19 (Crawled : 20:00) - globenewswire.com
HEPA | $2.1 -1.41% 6.2K |

Health Technology

| Email alert Add to watchlist
liver conference review pharmaceuticals topline trial results phase 2

---

Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2023-01-09 (Crawled : 13:00) - biospace.com/
TAK | $13.215 0.49% 210K |

Health Technology

| -15.6% | O: 0.13% H: 0.38% C: -0.19%
ARWR | $22.33 -0.89% 170K |

Health Technology

| -36.68% | O: -19.61% H: 3.16% C: 0.77%
liver disease topline results study

---

Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
Published: 2023-01-06 (Crawled : 13:20) - globenewswire.com
MDGL M | $224.7 -1.59% 87K |

Health Technology

| -15.96% | O: 0.18% H: 3.75% C: 3.28%
treatment fibrosis liver trial positive nash

---

Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
CMMB | $0.629 6.61% 17K |

Manufacturing

| -79.35% | O: 50.31% H: 11.23% C: -38.88%
cm-101 fibrosis liver biomarker trial results nash phase 2b

---

Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
Published: 2022-12-20 (Crawled : 12:20) - globenewswire.com
ALT | $7.21 2.42% 1.1M |

Commercial Services

| -26.71% | O: -4.19% H: 21.16% C: 21.06%
liver disease topline trial positive results

---

Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis
Published: 2022-12-19 (Crawled : 13:00) - biospace.com/
MDGL M | $224.7 -1.59% 87K |

Health Technology

| 257.9% | O: 219.37% H: 0.0% C: 0.0%
treatment fibrosis liver topline trial positive nash

---

Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results
Published: 2022-12-08 (Crawled : 12:20) - biospace.com/
BTTX | $0.009 180K |

| -99.34% | O: -1.41% H: 8.56% C: 3.59%
liver disease topline trial therapeutics positive

---

GENFIT Announces Compelling Results for Next-Generation Non-Invasive Diagnostic Technology NIS2+™ in NASH to be Presented at the AASLD Liver Meeting®
Published: 2022-10-25 (Crawled : 21:00) - globenewswire.com
GNFT | $3.63 2.4K |

Health Technology

| -13.16% | O: -2.39% H: 2.94% C: -1.72%
meeting liver diagnostic technology nash

---

Poxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022 POXEL SA announced that its late-breaking abstract describing the results from its Phase 2 study of PXL065...
Published: 2022-10-12 (Crawled : 07:00) - biospace.com/
NKTR | News | $1.295 -4.07% 1.1M |

Health Technology

| -62.08% | O: -1.69% H: 3.29% C: 0.57%
pxl065 meeting liver nash study phase 2

---

Eiger BioPharmaceuticals Announces Results from Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022
Published: 2022-06-27 (Crawled : 23:00) - biospace.com/
EIGR | $1.725 -1.45% 140K |

Health Technology

| -72.36% | O: 0.96% H: 3.97% C: 2.06%
liver international

---

Telos Corporation Announces Fourth Quarter Results: Delivers 43% Sales Growth and Expands Gross Margin 196 Basis Points; Issues 2022 Guidance
Published: 2022-03-16 (Crawled : 12:00) - globenewswire.com
TLS | $3.335 1.06% 23K |

Technology Services

| -66.05% | O: -6.69% H: 0.0% C: 0.0%
sales liver corporation results growth

---

Gainers vs Losers

83%

17%

Top 10 Gainers

AGBA | $0.7995 99.88% 73M |

Finance

BPTH | $6.21 91.67% 58M |

Health Technology

INVO | $1.36 78.95% 3.6M |

Health Technology

TIRX | $0.8258 70.34% 50M |

ISPC | $0.307 44.13% 3.6M |

Professional, Scientific, and T...

SINT | $0.0504 35.12% 300M |

Health Technology

VTNR S | $1.295 32.25% 5.5M |

Industrial Services

ALRN | $5.53 30.12% 250K |

Health Technology

SMSI 4 | $2.53 29.74% 510K |

Technology Services

HOLO | $2.86 27.68% 28M |

---

Your saved searches

---